Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen | PLOS ONE
Cabazitaxel for the treatment of castration-resistant prostate cancer | Future Oncology
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer - Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier ...
Lu-177 Vipivotide Tetraxetan Yields Similar OS Versus Cabazitaxel in mCRPC Progressing After Docetaxel
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial - The Lancet Oncology
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan | BMC Cancer | Full Text
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - ScienceDirect
Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI - ScienceDirect
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial - The Lancet
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study | Anticancer Research
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)
Kaplan–Meier curves of overall survival by treatment group (TROPIC... | Download Scientific Diagram
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Cancers | Free Full-Text | Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study | BMC Cancer | Full Text
ASCO 2022: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Journal of Clinical Oncology on X: "Cabazitaxel vs docetaxel as 1st line tx for metastatic castration-resistant prostate cancer (FIRSTANA trial) https://t.co/0DliBtSjsc #pcsm https://t.co/ZEHKYfmO8L" / X
